TOP TEN perturbations for 39432_at (Homo sapiens)
Organism: Homo sapiens
Gene: 39432_at
Selected probe(set): 212876_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 39432_at (212876_at) across 6674 perturbations tested by GENEVESTIGATOR:
pancreatic cancer study 3 (ipmn) / normal pancreas tissue
Relative Expression (log2-ratio):2.2808504Number of Samples:3 / 6
| Experimental | pancreatic cancer study 3 (ipmn) |
| Intraductal papillary mucinous neoplasm from patients with pancreatic cancer. | |
| Control | normal pancreas tissue |
| Normal human pancreatic tissue. |
pancreatic cancer study 3 (ipmc) / normal pancreas tissue
Relative Expression (log2-ratio):2.0909624Number of Samples:6 / 6
| Experimental | pancreatic cancer study 3 (ipmc) |
| Intraductal papillary mucinous carcinoma from patients with pancreatic cancer. | |
| Control | normal pancreas tissue |
| Normal human pancreatic tissue. |
CD44s overexpr. study 1 / normal HEK-293 cell sample
Relative Expression (log2-ratio):2.071763Number of Samples:3 / 3
| Experimental | CD44s overexpr. study 1 |
| Human embryonic kidney cell line HEK-293 transfected with pcDNA3.1(-) vector containing codon-optimized human CD44 sequence for expression. | |
| Control | normal HEK-293 cell sample |
| Untransfected, native human embryonic kidney cell line HEK-293 cell samples. |
stem cell differentiation study 41 (T3pi) / stem cell differentiation study 41 (hES-T3 EB)
Relative Expression (log2-ratio):-2.042059Number of Samples:2 / 2
| Experimental | stem cell differentiation study 41 (T3pi) |
| Sample of pancreatic islet-like cell clusters differentiated from human embryonic stem cells T3 with female karyotype. | |
| Control | stem cell differentiation study 41 (hES-T3 EB) |
| Sample of embryonic bodies (EB) differentiated from human embryonic stem cells T3 with female karyotype. |
pancreatic cancer study 3 (ipma) / normal pancreas tissue
Relative Expression (log2-ratio):2.0099077Number of Samples:6 / 6
| Experimental | pancreatic cancer study 3 (ipma) |
| Intraductal papillary mucinous adenoma from patients with pancreatic cancer. | |
| Control | normal pancreas tissue |
| Normal human pancreatic tissue. |
ovarian tumor study 30 (PDX; clear cell adenocarcinoma, NOS; primary) / ovarian tumor study 30 (PDX; adenocarcinoma, NOS; primary)
Relative Expression (log2-ratio):-2.0010347Number of Samples:2 / 2
| Experimental | ovarian tumor study 30 (PDX; clear cell adenocarcinoma, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary clear cell adenocarcinoma, NOS of the ovary (subcutaneously implanted). | |
| Control | ovarian tumor study 30 (PDX; adenocarcinoma, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary adenocarcinoma, NOS of the ovary (subcutaneously implanted). |
esophagus cancer study 1 (PDX; squamous cell carcinoma, NOS; metastatic) / esophagus cancer study 1 (PDX; squamous cell carcinoma, NOS; primary)
Relative Expression (log2-ratio):-1.9167948Number of Samples:2 / 3
| Experimental | esophagus cancer study 1 (PDX; squamous cell carcinoma, NOS; metastatic) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from a metastasis of patients with primary squamous cell carcinoma, NOS of the oesophagus (subcutaneously implanted). Metastatic site of patient tumor sample is not reported. | |
| Control | esophagus cancer study 1 (PDX; squamous cell carcinoma, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary squamous cell carcinoma, NOS of the oesophagus (subcutaneously implanted). |
dendritic cell study 6 (gardiquimod) / dendritic cell study 6 (untreated)
Relative Expression (log2-ratio):1.8271418Number of Samples:7 / 8
| Experimental | dendritic cell study 6 (gardiquimod) |
| Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors and treated with gardiquimod (TLR7 agonist) for 3 hours. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+. | |
| Control | dendritic cell study 6 (untreated) |
| Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+. |
HCC827 / A-549
Relative Expression (log2-ratio):-1.7911663Number of Samples:6 / 6
| Experimental | HCC827 |
| Human primary cancer cell line derived from the lung of a patient with non-small-cell lung cancer. Synonyms:HCC-827; HCC0827 Cellosaurus code: | |
| Control | A-549 |
| Human primary cancer cell line derived from the lung of a patient with carcinoma. Synonyms:A 549; A549; NCI-A549; A549/ATCC; hA549 Cellosaurus code: |
dendritic cell study 6 (gardiquimod; RN486) / dendritic cell study 6 (untreated)
Relative Expression (log2-ratio):1.6764383Number of Samples:4 / 8
| Experimental | dendritic cell study 6 (gardiquimod; RN486) |
| Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors and treated with gardiquimod (TLR7 agonist) and RN486 (Bruton’s tyrosine kinase; BTK inhibitor) for 3 hours. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+. | |
| Control | dendritic cell study 6 (untreated) |
| Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+. |